Document 0867
 DOCN  M9550867
 TI    Clinical pharmacokinetics of nucleoside antiretroviral agents.
 DT    9505
 AU    Dudley MN; Antiinfective Pharmacology Research Unit, University of
       Rhode; Island College of Pharmacy, Roger Williams Medical Center,;
       Providence 02908.
 SO    J Infect Dis. 1995 Mar;171 Suppl 2:S99-112. Unique Identifier : AIDSLINE
       MED/95164996
 AB    The rapid clinical evaluation of new drugs active against human
       immunodeficiency virus (HIV) requires that pharmacologic properties be
       carefully considered to determine optimal exposure profiles in patients.
       The published pharmacokinetic data for the nucleoside antiretroviral
       agents zidovudine, didanosine, zalcitabine, stavudine, and lamivudine
       show that administration of fixed doses of certain agents results in a
       considerable degree of between-patient variability in in vivo drug
       exposure. Pharmacologic treatment of HIV infection requires development
       of strategies for individualized adjustment of doses of certain agents
       with a high degree of interpatient variability.
 DE    Animal  Didanosine/PHARMACOKINETICS
       Dideoxynucleosides/*PHARMACOKINETICS/THERAPEUTIC USE  Human  HIV
       Infections/*DRUG THERAPY/METABOLISM  Stavudine/PHARMACOKINETICS
       Zalcitabine/ANALOGS & DERIVATIVES/PHARMACOKINETICS
       Zidovudine/PHARMACOKINETICS  JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).